Grain Brain — David Perlmutter: sugar, gluten and brain metabolism
Ukraine, Dnepr, st. 25 Sicheslavskaya Brigade (Rybinskaya St.), 119 ‑ 120
Ukraine, Dnepr, st. 25 Sicheslavskaya Brigade (Rybinskaya St.), 119 ‑ 120

Grain Brain — David Perlmutter: sugar, gluten and brain metabolism

A review of David Perlmutter's "Grain Brain" (2013): the "Alzheimer's = type 3 diabetes" concept, blood glucose and dementia risk, gluten and coeliac disease, ketone bodies as brain fuel — what human studies confirm and how to apply it.

Grain Brain — David Perlmutter: sugar, gluten and brain metabolism
David Perlmutter, a neurologist in Naples (Florida), formulates three theses in "Grain Brain" (2013): hyperglycaemia is the principal modifiable risk factor for neurodegeneration (Alzheimer's as type 3 diabetes); gluten is a neuroinflammatory trigger even in patients without coeliac disease; ketone bodies are an alternative energy substrate for a brain with impaired glucose utilisation. I look at what has been confirmed in humans and how to apply it in practice.

Key points

David Perlmutter is a practising neurologist in Naples (Florida) and a Fellow of the American College of Nutrition; his book "Grain Brain" (Little, Brown, 2013) was a #1 New York Times bestseller that brought the concept of brain metabolic health to a mass audience — here are its main ideas.

Idea of the bookHow it helps a personWhat human studies showed
Alzheimer's disease is in large part a metabolic disease of the brain associated with insulin resistance ("type 3 diabetes")neurodegeneration begins decades before clinical signs and is modifiable by metabolic means, so metabolic health is the priority for primary preventiondiabetes is a risk factor for dementia (Crane PK et al., NEJM 2013); brain insulin resistance is confirmed in postmortem tissue from Alzheimer's patients (Talbot K et al., J Clin Invest 2012)
Hyperglycaemia is a modifiable risk factor for neurodegenerationblood glucose can be influenced: minimise refined sugars and starches and take carbohydrates from whole sourcesblood glucose level, even in the subdiabetic range, correlates directly with dementia risk in a prospective cohort (Crane PK et al., NEJM 2013, PMID 23924004)
Gluten is not only about coeliac diseasehelps avoid missing coeliac disease and gluten sensitivity: serological screening when there are symptoms, an elimination trial if suspicion remainscoeliac disease (1% of the population) is an autoimmune disease treated by lifelong gluten exclusion; in non-coeliac gluten sensitivity (NCGS, about 6% of the population) symptomatic patients without features of coeliac disease improve on a gluten-free diet and relapse on challenge (Volta U et al., BMC Med 2014)
Ketone bodies are an alternative fuel for the brainwhen glucose utilisation is impaired, the brain can draw energy from ketone bodies, which are independent of insulin signallingthe brain in early Alzheimer's shows a deficit of glucose metabolism with preserved utilisation of ketone bodies ([11C]acetoacetate PET; Cunnane SC et al., Nat Rev Drug Discov 2020, PMID 32709961); in an RCT of the ketogenic agent AC-1202 in 152 patients with mild to moderate Alzheimer's disease, the cognitive score on day 45 was better than with placebo (Henderson ST et al., Nutr Metab 2009, PMID 19664276); the ketogenic diet has been a standard therapy for refractory paediatric epilepsy since the 1920s, with reliable efficacy

What the book's ideas offer

Alzheimer's as "type 3 diabetes"

The strongest thesis of the book: Alzheimer's disease is in large part a metabolic disease of the brain associated with insulin resistance. The "type 3 diabetes" concept, proposed by Suzanne de la Monte (Brown University, J Diabetes Sci Technol 2008), describes how the Alzheimer's brain demonstrates the characteristic features of insulin resistance: reduced expression of insulin receptors in the hippocampus, impaired signalling, dysfunctional glucose metabolism (visible on FDG-PET 10–15 years before clinical symptoms).

APOE4 carriers carry a heightened predisposition to Alzheimer's, and this association is modified by metabolic factors (diabetes, obesity).

The relationship is bidirectional and mechanistically logical. Insulin resistance reduces glucose uptake by neurons (the brain accounts for 20% of whole-body glucose metabolism). Neurons enter an energy deficit. In parallel β-amyloid is a by-product of impaired APP processing under conditions of hyperglycaemia and oxidative stress. Chronic energy deficit plus β-amyloid accumulation gives clinical disease 15–30 years later.

Gluten and the gut

The second central thesis of the book: Perlmutter argues that gluten has a neuroinflammatory effect even in patients without coeliac disease. Beyond the data in the table, the following is well established:
- Coeliac disease is a clinically reliable autoimmune disease with robust serological diagnosis (anti-tTG, anti-EMA, anti-DGP) and endoscopic confirmation. Treatment is lifelong gluten exclusion. This is mainstream medicine
- Zonulin-mediated increases in intestinal permeability in susceptible individuals under a gluten load (Fasano A, Physiol Rev 2011, PMID 21248165) — a defensible biological model

Ketones as an alternative fuel

The third idea is the ketogenic diet as a neuroprotective regime. The logic: when glucose utilisation is impaired (pre-diabetes, early neurodegeneration), the brain does not receive enough energy. Ketone bodies (β-hydroxybutyrate, acetoacetate) are an alternative energy substrate independent of insulin signalling.

How to apply it

What can be taken from Perlmutter's ideas in clinical practice:

Brain metabolic health: in my practice patients with APOE4 status or a family history of Alzheimer's have metabolic health as the priority for primary prevention: it is a shift in metabolic risk that accumulates over decades before manifestation. ApoB and Lp(a) cover the vascular component. The targets below are the baseline infrastructure for long-term neuroprotection.

MarkerTarget
HbA1c< 5.4%
HOMA-IR< 1.5
ApoB< 80 mg/dL
Omega-3 index> 8%
25(OH)D40–60 ng/mL

Carbohydrates: minimise refined sugars and starches. Carbohydrates from whole sources (legumes, vegetables, whole grains, fruit with skin) remain. Glycaemic index and load are control parameters for patients with insulin resistance.

Gluten: I screen serologically for coeliac disease (anti-tTG IgA plus total IgA) in patients with any gastrointestinal symptoms, unexplained anaemia, autoimmune thyroiditis and other autoimmune diseases, depression, neuropathy or infertility. If screening is negative and suspicion remains, I consider a 6–8 week elimination trial with a mandatory subsequent challenge. That is a reasonable empirical clinical tool with an acceptable risk/benefit balance.

Ketone bodies: in my practice the ketogenic regime is a therapeutic tool with specific indications: insulin resistance with metabolic syndrome (short cycles of 6–12 weeks), early cognitive impairment in APOE4 carriers (when indicated, with monitoring), and some epilepsies. For prevention in healthy patients, restriction of sugar and refined carbohydrates without full ketosis is sufficient. Baseline intake of healthy fats (fish, olive oil, nuts) and episodic intermittent fasting of 12–14 hours is already moderate stimulation of ketosis without a full ketogenic diet.

Inflammation markers: hsCRP, homocysteine, GGT, omega-3 index — simple indicators of the systemic inflammatory background relevant to the brain.

Who should see a doctor first

The ketogenic diet has significant limitations:
- Not suitable in hypothyroidism (low carbohydrate intake reduces T4-to-T3 conversion)
- Risk of menstrual disturbance in women of reproductive age
- Contraindicated in adrenal disease, glycogen storage disease, carnitine deficiency, and biliary disease
- Long-term safety data in healthy adults are limited; there are signals of dyslipidaemia (rising ApoB in some patients), renal function disturbance and microbiome shifts

  • Gluten: not grounds for self-exclusion without diagnosis — for a significant fraction of patients this creates nutritional risks without clinical benefit. Elimination trial with mandatory challenge — only under clinical supervision
  • Dementia: for the treatment of established dementia the standard remains in neurology
  • Blood sugar: if you don't have diabetes and your blood sugar is repeatedly below 3.0 mmol/L (54 mg/dL) or above 8.9 mmol/L (160 mg/dL) — see a doctor

Bottom line

What is strong in the book: the metabolic nature of Alzheimer's as type 3 diabetes; the link between HbA1c and neurodegeneration risk; the role of ketone utilisation in brain energetics; the idea that neurodegeneration is a process beginning decades before clinical signs and modifiable by metabolic means. The principal biological concepts — the link between metabolic health and the brain, the metabolic nature of Alzheimer's, gut-brain neuroactivity — are sound and merit serious attention.

The book is for a healthy person who wants to understand the metabolic roots of neurodegeneration and optimise their diet.

About the reviewer

Dr. Vladimir Pereligyn — endocrinologist. Functional medicine with a focus on preventive strategies: metabolic health, thyroid function, hormonal balance, and individualised risk profiling based on extended laboratory diagnostics. Consultations in person and online: universum.earth/consultation. App Store: Teremok (type 2 diabetes, remission).

Source

▸  Perlmutter D, Loberg K. Grain Brain: The Surprising Truth about Wheat, Carbs, and Sugar — Your Brain's Silent Killers. Little, Brown and Company, New York, 2013. ISBN 978-0316234801. 336 pages.

Further reading on the topics of this review:
▸  de la Monte SM, Wands JR. Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol 2008;2(6):1101-13.
▸  Crane PK, Walker R, Hubbard RA, et al. Glucose levels and risk of dementia. N Engl J Med 2013;369(6):540-8. PMID 23924004
▸  Talbot K, Wang HY, Kazi H, et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 2012;122(4):1316-38.
▸  Volta U, Bardella MT, Calabrò A, et al. An Italian prospective multicenter survey on patients suspected of having non-celiac gluten sensitivity. BMC Med 2014;12:85.
▸  Cunnane SC, Trushina E, Morland C, et al. Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing. Nat Rev Drug Discov 2020;19(9):609-633. PMID 32709961

Source: Grain Brain — David Perlmutter: sugar, gluten and brain metabolism — universum.earth. md_pereligyn — Перелыгин Владимир Игоревич.

Come back
Request a call back